Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity
Milan Bruncko(Abbott Fund), Andrew J. Souers(AbbVie (United States)), Paul Nimmer(Abbott Fund), Chris Tse(AbbVie (United States)), Sha Jin(AbbVie (United States)), Russell A. Judge(AbbVie (United States)), David J. Madar(AbbVie (United States)), Darren C. Phillips(AbbVie (United States)), Xiao Yu(Huazhong Agricultural University), Scott Erickson(AbbVie (United States)), Gary J. Jenkins(AbbVie (United States)), Lisa Hasvold(AbbVie (United States)), Morey L. Smith(AbbVie (United States)), Xilu Wang(AbbVie (United States)), George S. Sheppard(AbbVie (United States)), Zhi‐Fu Tao(AbbVie (United States)), Andrew M. Petros(Abbott Fund), Elizabeth E. Fry(University of Oxford), Joel D. Leverson(AbbVie (United States)), Le Wang(Rutgers, The State University of New Jersey), Xiaohong Song(Abbott (United States)), Haichao Zhang(Abbott Fund), Stephen K. Tahir(Abbott Fund), Steven W. Elmore(AbbVie (United States)), Steve Fidanze(AbbVie (United States)), Chang Park(AbbVie (United States)), John Xue(AbbVie (United States)), Chaohong Sun(AbbVie (United States)), Saul H. Rosenberg(Abbott Fund), Peter Kovar(AbbVie (United States))
Cited by 152
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k